NO312397B1 - Enteriske duloxetinpellets - Google Patents
Enteriske duloxetinpellets Download PDFInfo
- Publication number
- NO312397B1 NO312397B1 NO19952786A NO952786A NO312397B1 NO 312397 B1 NO312397 B1 NO 312397B1 NO 19952786 A NO19952786 A NO 19952786A NO 952786 A NO952786 A NO 952786A NO 312397 B1 NO312397 B1 NO 312397B1
- Authority
- NO
- Norway
- Prior art keywords
- duloxetine
- layer
- enteric
- suspension
- product
- Prior art date
Links
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 title claims description 81
- 229960002866 duloxetine Drugs 0.000 title claims description 80
- 239000008188 pellet Substances 0.000 title claims description 55
- 239000010410 layer Substances 0.000 claims description 70
- 238000000926 separation method Methods 0.000 claims description 31
- 239000011324 bead Substances 0.000 claims description 27
- 239000012055 enteric layer Substances 0.000 claims description 22
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 19
- 239000002245 particle Substances 0.000 claims description 19
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 16
- 229930006000 Sucrose Natural products 0.000 claims description 4
- -1 ammonium ions Chemical class 0.000 claims description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid group Chemical group C(CCC(=O)O)(=O)O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 3
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 229920000642 polymer Polymers 0.000 description 44
- 239000000047 product Substances 0.000 description 40
- 239000000725 suspension Substances 0.000 description 37
- 239000000463 material Substances 0.000 description 24
- 238000000034 method Methods 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- 239000000454 talc Substances 0.000 description 17
- 229910052623 talc Inorganic materials 0.000 description 17
- 239000002775 capsule Substances 0.000 description 14
- 238000000576 coating method Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000007903 gelatin capsule Substances 0.000 description 8
- 238000006386 neutralization reaction Methods 0.000 description 8
- 238000005507 spraying Methods 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000009505 enteric coating Methods 0.000 description 6
- 239000002702 enteric coating Substances 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical group CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 description 5
- 230000001427 coherent effect Effects 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000001069 triethyl citrate Substances 0.000 description 5
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 5
- 235000013769 triethyl citrate Nutrition 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 239000004408 titanium dioxide Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000003605 opacifier Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000011049 pearl Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229960001866 silicon dioxide Drugs 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229920001938 Vegetable gum Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012792 core layer Substances 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 235000013980 iron oxide Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960004029 silicic acid Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 229940033134 talc Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 241000220479 Acacia Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000009496 sugar coating process Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/276,232 US5508276A (en) | 1994-07-18 | 1994-07-18 | Duloxetine enteric pellets |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO952786D0 NO952786D0 (no) | 1995-07-13 |
| NO952786L NO952786L (no) | 1996-01-19 |
| NO312397B1 true NO312397B1 (no) | 2002-05-06 |
Family
ID=23055767
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19952786A NO312397B1 (no) | 1994-07-18 | 1995-07-13 | Enteriske duloxetinpellets |
| NO2005002C NO2005002I2 (no) | 1994-07-18 | 2005-02-01 | Duloksetin |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2005002C NO2005002I2 (no) | 1994-07-18 | 2005-02-01 | Duloksetin |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US5508276A (fr) |
| EP (1) | EP0693282B1 (fr) |
| JP (1) | JP3707831B2 (fr) |
| KR (1) | KR100356240B1 (fr) |
| CN (1) | CN1106191C (fr) |
| AT (1) | ATE200620T1 (fr) |
| AU (1) | AU686384B2 (fr) |
| BR (1) | BR9503346A (fr) |
| CA (1) | CA2153856C (fr) |
| CO (1) | CO4410177A1 (fr) |
| CZ (1) | CZ288095B6 (fr) |
| DE (1) | DE69520711T2 (fr) |
| DK (1) | DK0693282T3 (fr) |
| ES (1) | ES2157297T3 (fr) |
| GE (1) | GEP20063944B (fr) |
| GR (1) | GR3036185T3 (fr) |
| HU (1) | HU221502B (fr) |
| IL (1) | IL114584A (fr) |
| MY (1) | MY116361A (fr) |
| NO (2) | NO312397B1 (fr) |
| NZ (1) | NZ272554A (fr) |
| PE (1) | PE32196A1 (fr) |
| PL (1) | PL181296B1 (fr) |
| PT (1) | PT693282E (fr) |
| RU (1) | RU2147231C1 (fr) |
| SI (1) | SI0693282T1 (fr) |
| TW (1) | TW382596B (fr) |
| UA (1) | UA41344C2 (fr) |
| YU (1) | YU49445B (fr) |
| ZA (1) | ZA955799B (fr) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11510143A (ja) * | 1995-07-24 | 1999-09-07 | イーライ・リリー・アンド・カンパニー | 注意不足／活動亢進障害の処置 |
| US5910319A (en) * | 1997-05-29 | 1999-06-08 | Eli Lilly And Company | Fluoxetine enteric pellets and methods for their preparation and use |
| ATE449603T1 (de) * | 1998-09-15 | 2009-12-15 | Lilly Co Eli | Verwendung von duloxetine zur behandlung von fibromyalgie |
| EP1970052A2 (fr) * | 1999-02-09 | 2008-09-17 | Pfizer Products Inc. | Compositions de médicaments basiques avec une meilleure biodisponibilité |
| IL130602A0 (en) * | 1999-06-22 | 2000-06-01 | Dexcel Ltd | Stable benzimidazole formulation |
| EA200200948A1 (ru) * | 2000-03-07 | 2003-02-27 | Эли Лилли Энд Компани | Лечение псориаза |
| EP1383495A1 (fr) * | 2001-03-29 | 2004-01-28 | Eli Lilly And Company | Duloxetine pour le traitement de la bouffee de chaleur |
| EP1404300B1 (fr) | 2001-06-22 | 2009-09-30 | Pfizer Products Inc. | Compositions pharmaceutiques de dispersions de medicaments et de polymeres neutres |
| OA12624A (en) * | 2001-06-22 | 2006-06-12 | Pfizer Prod Inc | Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers. |
| EP1565182A1 (fr) * | 2002-11-19 | 2005-08-24 | Eli Lilly And Company | Traitement des troubles gastro-intestinaux par administration de duloxetine |
| EP1648421B1 (fr) * | 2003-07-24 | 2017-10-18 | GlaxoSmithKline LLC | Films a dissolution orale |
| WO2005097070A1 (fr) * | 2004-04-08 | 2005-10-20 | Kyowa Hakko Kogyo Co., Ltd. | Préparation pharmaceutique solide avec stabilité améliorée et son procédé de production |
| GB0410470D0 (en) * | 2004-05-11 | 2004-06-16 | Cipla Ltd | Pharmaceutical compound and polymorphs thereof |
| TWI306858B (en) * | 2004-12-23 | 2009-03-01 | Teva Pharma | Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof |
| US7399871B2 (en) * | 2005-03-08 | 2008-07-15 | Teva Pharmaceutical Industries Ltd. | Crystal forms of (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine oxalate and the preparation thereof |
| TW200639162A (en) * | 2005-03-14 | 2006-11-16 | Teva Pharma | Pure duloxetine hydrochloride |
| EP1904039A2 (fr) * | 2005-06-20 | 2008-04-02 | Cadila Healthcare Ltd. | Formulation galenique a liberation commandee de duloxetine |
| US8153824B2 (en) * | 2005-06-22 | 2012-04-10 | The Wockhardt Company | Antidepressant oral liquid compositions |
| SI1915137T1 (sl) | 2005-08-10 | 2013-12-31 | Add Advanced Drug Delivery Technologies, Ltd. | Pripravek z nadzorovanim sproščanjem za peroralno dajanje |
| US20060165776A1 (en) * | 2005-08-31 | 2006-07-27 | Ramesh Sesha | Antidepressant oral pharmaceutical compositions |
| US20080207923A1 (en) * | 2005-09-22 | 2008-08-28 | Santiago Ini | Pure DNT-maleate and methods of preparation thereof |
| EP1838692A2 (fr) * | 2005-09-22 | 2007-10-03 | Teva Pharmaceutical Industries Ltd | Dnt-maleate, procedes de preparation de dernier |
| WO2007062119A1 (fr) * | 2005-11-23 | 2007-05-31 | Auspex Pharmaceuticals, Inc. | Aryloxypropylamines substituées possédant une activité sérotoninergique et/ou norépinephrinergique |
| EP1863782A1 (fr) * | 2005-12-05 | 2007-12-12 | Teva Pharmaceutical Industries Ltd. | 2-(n-methyl-propanamine)-3-(2-naphtol)thiophene, une impurete du duloxetine chlorhydrate |
| DE102005060393A1 (de) * | 2005-12-16 | 2007-06-21 | Add Advanced Drug Delivery Technologies Ltd. | Orales Präparat mit kontrollierter Freisetzung |
| EP1844034A1 (fr) * | 2006-01-23 | 2007-10-17 | Teva Pharmaceutical Industries Ltd | Dnt-fumarate et méthodes de synthèse de celui-ci |
| EP1820800A1 (fr) * | 2006-02-17 | 2007-08-22 | KRKA, tovarna zdravil, d.d., Novo mesto | Formes crystalline de l'hydrochlorure de duloxetine et procédés pour leur préparations |
| KR200416582Y1 (ko) | 2006-03-07 | 2006-05-19 | 김정배 | 건강신발 |
| EP1919467A2 (fr) * | 2006-05-22 | 2008-05-14 | Teva Pharmaceutical Industries Ltd | Formulations a liberation retardee de chlorhydrate de duloxetine |
| MX2008001079A (es) * | 2006-05-23 | 2008-03-19 | Teva Pharma | Polimorfos de hidrocloruro de duloxetina. |
| JP5052051B2 (ja) * | 2006-06-16 | 2012-10-17 | トーアエイヨー株式会社 | 腸溶性顆粒剤及びその製造方法 |
| WO2008020286A2 (fr) * | 2006-08-14 | 2008-02-21 | Torrent Pharmaceuticals Limited | Compositions pharmaceutiques de duloxétine |
| CN101190208B (zh) * | 2006-11-30 | 2011-11-02 | 石药集团中奇制药技术（石家庄）有限公司 | 一种含有盐酸度洛西汀的药物制剂及其制备方法 |
| WO2008077645A1 (fr) | 2006-12-22 | 2008-07-03 | Synthon B.V. | Procédé de fabrication de la duloxétine et de composés apparentés |
| EP2018860A1 (fr) * | 2007-07-16 | 2009-01-28 | LEK Pharmaceuticals D.D. | Composition de duloxétine |
| EP2099492B1 (fr) * | 2006-12-27 | 2013-06-05 | LEK Pharmaceuticals d.d. | Composition a base de duloxetine |
| EP1938840A1 (fr) * | 2006-12-27 | 2008-07-02 | LEK Pharmaceuticals D.D. | Composition à base de Duletoxine |
| US20080226711A1 (en) * | 2007-03-12 | 2008-09-18 | Torrent Pharmaceuticals Ltd. | Pharmaceutical compositions of duloxetine |
| WO2008129501A2 (fr) * | 2007-04-20 | 2008-10-30 | Wockhardt Research Centre | Compositions pharmaceutiques de duloxetine |
| WO2009004649A2 (fr) * | 2007-05-21 | 2009-01-08 | Sun Pharmaceutical Industries Limited | Compositions pharmaceutiques à revêtement entérique |
| GB0712220D0 (en) * | 2007-06-23 | 2007-08-01 | Arrow Int Ltd | Duloxetine formulation |
| WO2009066181A2 (fr) * | 2007-07-09 | 2009-05-28 | Combino Pharm, S.L. | Pastilles de chlorhydrate de duloxétine pour administration orale à libération retardée |
| EP2182929A2 (fr) * | 2007-07-13 | 2010-05-12 | Synthon B.V. | Formulations de duloxétine |
| WO2009087657A2 (fr) * | 2007-11-03 | 2009-07-16 | Alkem Laboratories Ltd. | Composition pharmaceutique stable de duloxétine et son procédé de préparation |
| US9233078B2 (en) | 2007-12-06 | 2016-01-12 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer |
| WO2009073215A1 (fr) * | 2007-12-06 | 2009-06-11 | Bend Research, Inc. | Compositions pharmaceutiques comprenant des nanoparticules et une matière de remise en suspension |
| EP2240173A4 (fr) * | 2008-01-25 | 2013-07-17 | Alphapharm Pty Ltd | Composition pharmaceutique de duloxétine à libération retardée |
| US20090226517A1 (en) * | 2008-02-06 | 2009-09-10 | Vinita Umashankar Vyas | Pharmaceutical formulations comprising duloxetine |
| AU2009230676A1 (en) * | 2008-03-24 | 2009-10-01 | Lupin Limited | Delayed release compositions of duloxetine |
| EP2293782B1 (fr) * | 2008-05-06 | 2015-08-12 | Dexcel Pharma Technologies Ltd. | Formule stable de benzimidazole |
| EP2133072A1 (fr) | 2008-06-13 | 2009-12-16 | KRKA, D.D., Novo Mesto | Compositions orales pharmaceutiques gastro-résistantes comportant du duloxétine ou ses dérivés pharmaceutiques acceptables |
| US20100040680A1 (en) * | 2008-08-15 | 2010-02-18 | Felix Lai | Multiparticulate selective serotonin and norepinephrine reuptake inhibitor formulation |
| WO2010037849A1 (fr) * | 2008-10-02 | 2010-04-08 | Laboratorios Del Dr. Esteve, S.A. | Pastilles de duloxétine gastro-résistantes |
| CN101756960B (zh) * | 2008-12-26 | 2012-06-27 | 上海中西制药有限公司 | 一种度洛西汀肠溶制剂及其芯材和制备方法 |
| WO2010078878A1 (fr) * | 2009-01-12 | 2010-07-15 | Synthon B.V. | Formulations de duloxétine |
| CA2765635C (fr) | 2009-06-25 | 2016-09-06 | Wockhardt Research Centre | Composition pharmaceutique de duloxetine ou ses sels pharmaceutiquement acceptables |
| DE102009033621A1 (de) | 2009-07-17 | 2011-01-20 | Add Technologies Ltd. | Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen |
| EP2477614A2 (fr) * | 2009-09-17 | 2012-07-25 | Cadila Healthcare Limited | Compositions pharmaceutiques pour réduire une libération massive induite par l'alcool |
| JP5714600B2 (ja) * | 2009-12-18 | 2015-05-07 | フリースランドカンピナ・ネーデルランド・ホールディング・ビー．ブイ．ＦｒｉｅｓｌａｎｄＣａｍｐｉｎａ Ｎｅｄｅｒｌａｎｄ Ｈｏｌｄｉｎｇ Ｂ．Ｖ． | 共加工された錠用賦形剤混合物、その調製及び使用 |
| EP2544667B1 (fr) * | 2010-03-09 | 2018-11-14 | Alkermes Pharma Ireland Limited | Compositions pharmaceutiques entériques résistantes aux alcools |
| EP2377525A1 (fr) * | 2010-03-26 | 2011-10-19 | Laboratorios del Dr. Esteve S.A. | Granulés entériques à la duloxétine |
| ES2601841T3 (es) * | 2010-05-25 | 2017-02-16 | Hetero Research Foundation | Composición farmacéutica oral de duloxetina |
| CN102908331A (zh) * | 2011-08-01 | 2013-02-06 | 浙江九洲药物科技有限公司 | 一种盐酸度洛西汀肠溶胶囊及其制备方法 |
| EP3187171B1 (fr) | 2012-04-30 | 2024-09-25 | Tillotts Pharma AG | Formulation de médicament à libération retardée |
| ES2728850T3 (es) | 2012-05-02 | 2019-10-29 | Capsugel Belgium Nv | Dispersiones acuosas de acetato acetato succinato de hidroxipropilmetilcelulosa (HPMCAS) |
| CN103505421B (zh) * | 2012-06-29 | 2018-04-27 | 石药集团中奇制药技术（石家庄）有限公司 | 一种盐酸度洛西汀的肠溶微丸制剂 |
| CN103211777A (zh) * | 2013-03-31 | 2013-07-24 | 北京万全阳光医学技术有限公司 | 一种盐酸度洛西汀的药物制剂及其制备的方法 |
| GR1008228B (el) * | 2013-04-23 | 2014-06-16 | "Φαρματεν Α.Β.Ε.Ε.", | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου |
| EP2813218B1 (fr) * | 2013-06-14 | 2022-08-24 | Shin-Etsu Chemical Co., Ltd. | Procédé de production de liquide d'enrobage entérosoluble aqueux, préparation solide et son procédé de production |
| CN103393615B (zh) * | 2013-07-24 | 2015-07-15 | 海南华益泰康药业有限公司 | 一种度洛西汀肠溶小丸及其制备方法 |
| PL224543B1 (pl) | 2013-08-21 | 2017-01-31 | Pabianickie Zakłady Farm Polfa Spółka Akcyjna | Dojelitowa tabletka duloksetyny |
| JP6273356B2 (ja) | 2013-10-29 | 2018-01-31 | ティロッツ・ファルマ・アクチエンゲゼルシャフトＴｉｌｌｏｔｔｓ Ｐｈａｒｍａ Ａｇ | 遅延放出性薬物製剤 |
| US20160256399A1 (en) | 2013-11-04 | 2016-09-08 | Capsugel Belgium Nv | Methods and systems for improved bioavailability of active pharmaceutical ingredients including esomeprazole |
| WO2015179073A1 (fr) * | 2014-05-20 | 2015-11-26 | Dow Global Technologies Llc | Enveloppes de capsule comprenant un éther de cellulose estérifié |
| EP3182970A4 (fr) * | 2014-08-22 | 2018-03-21 | Medipath Inc. | Compositions et procédés d'enrobages en cannabinoïdes utilisés dans l'administration de médicaments |
| US10471152B2 (en) * | 2014-08-29 | 2019-11-12 | Capsugel Belgium Nv | Colloidal dispersion comprising HPMCAS |
| US20170182070A1 (en) | 2014-10-08 | 2017-06-29 | Mayne Pharma International Pty Ltd. | Controlled Release Doxycycline |
| US9668975B2 (en) | 2014-10-14 | 2017-06-06 | PharmaDax Inc. | Method of preparing drug agglomerate |
| CN105726488B (zh) * | 2014-12-08 | 2020-10-20 | 上海爱科百发生物医药技术有限公司 | 含有呼吸道合胞病毒抑制剂的肠溶微丸及其制备方法 |
| KR101625344B1 (ko) | 2015-12-21 | 2016-06-08 | 주식회사 유영제약 | 세레콕시브 및 둘록세틴을 함유하는 약제학적 조성물 |
| CN105534949A (zh) * | 2016-01-06 | 2016-05-04 | 北京修正创新药物研究院有限公司 | 一种盐酸度洛西汀的肠溶微丸制剂 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| JP6815109B2 (ja) * | 2016-06-23 | 2021-01-20 | キョーリンリメディオ株式会社 | デュロキセチンまたは薬学的に許容されるその塩を有効成分とする医薬組成物 |
| JP6856326B2 (ja) * | 2016-07-15 | 2021-04-07 | 富士化学工業株式会社 | 腸放出粒子組成物 |
| CN106166144A (zh) * | 2016-08-12 | 2016-11-30 | 海南合瑞制药股份有限公司 | 一种盐酸度洛西汀肠溶胶囊药物组合物 |
| JP2018172361A (ja) * | 2016-10-14 | 2018-11-08 | 大原薬品工業株式会社 | 光安定性を改善した、デュロキセチンを含有する固形製剤 |
| US9839626B1 (en) * | 2016-12-14 | 2017-12-12 | Sun Pharmaceutical Industries Limited | Duloxetine sprinkles |
| JP7072431B2 (ja) * | 2017-04-14 | 2022-05-20 | 富士化学工業株式会社 | 錠剤及びその製造方法 |
| JP6972674B2 (ja) * | 2017-06-06 | 2021-11-24 | ニプロ株式会社 | 経口医薬製剤 |
| JP2020029447A (ja) * | 2018-06-25 | 2020-02-27 | 大原薬品工業株式会社 | 腸溶性高分子及び抗付着剤を含有する顆粒 |
| CN110420195B (zh) * | 2018-10-25 | 2022-12-06 | 上海上药中西制药有限公司 | 盐酸度洛西汀肠溶制剂、其主药层及其混悬液、其隔离层及其包衣液、及其制备方法 |
| JP7050714B2 (ja) * | 2019-04-04 | 2022-04-08 | 信越化学工業株式会社 | 腸溶性コーティング用組成物及び固形製剤の製造方法 |
| JP2020189815A (ja) * | 2019-05-23 | 2020-11-26 | 東和薬品株式会社 | デュロキセチン製剤およびその安定化方法 |
| US20220265659A1 (en) | 2019-09-02 | 2022-08-25 | Inserm (Institut National De La Santé Et De Al Recherche Médicale) | Methods and compositions for treating pax6-deficiency related disease |
| WO2021126099A1 (fr) * | 2019-12-18 | 2021-06-24 | Santa Farma İlaç Sanayi̇ A.Ş. | Pastille à enrobage entérique comprenant du chlorhydrate de duloxétine avec des degrés de neutralisation optimisés |
| WO2021126098A1 (fr) * | 2019-12-18 | 2021-06-24 | Santa Farma İlaç Sanayi̇ A.Ş. | Pastille gastro-résistante comprenant de la duloxétine |
| WO2022115054A1 (fr) * | 2020-11-27 | 2022-06-02 | Santa Farma Ilac Sanayii A.S. | Compositions de duloxétine à enrobage entérique |
| WO2024117996A1 (fr) * | 2022-11-30 | 2024-06-06 | Santa Farma Ilac Sanayii A.S. | Composition pharmaceutique orale bioéquivalente comprenant du chlorhydrate de duloxétine |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS517116A (en) * | 1974-06-11 | 1976-01-21 | Shinetsu Chemical Co | Choyoseihifukuyakuzaino seizohoho |
| CH649216A5 (de) * | 1979-08-16 | 1985-05-15 | Sandoz Ag | Verfahren zur auftragung eines magensaftresistenten filmes auf einen heilmittelkern und feste einheitsdosierungsform mit magensaftresistentem film. |
| US5019302A (en) | 1986-03-12 | 1991-05-28 | Washington University Technology Associates, Inc. | Method for granulation |
| US5100592A (en) | 1986-03-12 | 1992-03-31 | Washington University Technology Associated, Inc. | Method and apparatus for granulation and granulated product |
| GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| JP2773959B2 (ja) * | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| JPH04346930A (ja) * | 1991-05-25 | 1992-12-02 | Sumitomo Pharmaceut Co Ltd | 安定なアスピリン腸溶錠 |
| ZA93694B (en) * | 1993-02-01 | 1993-06-03 | Lilly Co Eli | Pharmaceutical treatments. |
| US5362886A (en) * | 1993-10-12 | 1994-11-08 | Eli Lilly And Company | Asymmetric synthesis |
-
1994
- 1994-07-18 US US08/276,232 patent/US5508276A/en not_active Expired - Lifetime
-
1995
- 1995-07-12 PL PL95309588A patent/PL181296B1/pl unknown
- 1995-07-12 TW TW084107228A patent/TW382596B/zh not_active IP Right Cessation
- 1995-07-12 CZ CZ19951805A patent/CZ288095B6/cs not_active IP Right Cessation
- 1995-07-12 NZ NZ272554A patent/NZ272554A/en not_active IP Right Cessation
- 1995-07-12 PE PE1995273613A patent/PE32196A1/es not_active IP Right Cessation
- 1995-07-12 ZA ZA955799A patent/ZA955799B/xx unknown
- 1995-07-13 IL IL11458495A patent/IL114584A/xx not_active IP Right Cessation
- 1995-07-13 MY MYPI95001986A patent/MY116361A/en unknown
- 1995-07-13 NO NO19952786A patent/NO312397B1/no not_active IP Right Cessation
- 1995-07-13 UA UA95073317A patent/UA41344C2/uk unknown
- 1995-07-13 CA CA002153856A patent/CA2153856C/fr not_active Expired - Lifetime
- 1995-07-14 CO CO95031237A patent/CO4410177A1/es unknown
- 1995-07-14 HU HU9502134A patent/HU221502B/hu unknown
- 1995-07-15 KR KR1019950020885A patent/KR100356240B1/ko not_active IP Right Cessation
- 1995-07-17 CN CN95108414A patent/CN1106191C/zh not_active Expired - Lifetime
- 1995-07-17 DK DK95304977T patent/DK0693282T3/da active
- 1995-07-17 BR BR9503346A patent/BR9503346A/pt not_active IP Right Cessation
- 1995-07-17 DE DE69520711T patent/DE69520711T2/de not_active Expired - Lifetime
- 1995-07-17 RU RU95113118A patent/RU2147231C1/ru active
- 1995-07-17 JP JP18002695A patent/JP3707831B2/ja not_active Expired - Lifetime
- 1995-07-17 ES ES95304977T patent/ES2157297T3/es not_active Expired - Lifetime
- 1995-07-17 AU AU25051/95A patent/AU686384B2/en not_active Expired
- 1995-07-17 EP EP95304977A patent/EP0693282B1/fr not_active Expired - Lifetime
- 1995-07-17 PT PT95304977T patent/PT693282E/pt unknown
- 1995-07-17 SI SI9530506T patent/SI0693282T1/xx unknown
- 1995-07-17 YU YU48095A patent/YU49445B/sh unknown
- 1995-07-17 AT AT95304977T patent/ATE200620T1/de active
-
2001
- 2001-07-06 GR GR20010401033T patent/GR3036185T3/el unknown
-
2005
- 2005-02-01 NO NO2005002C patent/NO2005002I2/no unknown
-
2006
- 2006-03-23 GE GEAP20069310A patent/GEP20063944B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO312397B1 (no) | Enteriske duloxetinpellets | |
| CA2234826C (fr) | Comprimes enteriques a base de fluoxetine | |
| CA2038245C (fr) | Micropellets utiles en pharmacologie | |
| EP1228125A2 (fr) | Procede relatif a la formation de granules a revetement aqueux | |
| CN101939004A (zh) | 度洛西汀的缓释药物组合物 | |
| JP2004525897A (ja) | 医薬処方 | |
| US20120003303A1 (en) | Oral enteric antidepressant formulation | |
| WO2011096953A1 (fr) | Formulation orale d'antidépresseur avec une charge réduite en excipients | |
| IE83510B1 (en) | Fluoxetine enteric pellets | |
| MXPA98003636A (es) | Granulos entericos de fluoxetina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: YENTREVE; NAT. REG. NO/DATE: EU104280001 20040826; FIRST REG. NO/DATE: DE , 203496 20040812 Spc suppl protection certif: 2005002 Filing date: 20050201 Extension date: 20190811 Effective date: 20091005 |
|
| MK1K | Patent expired | ||
| SPCX | Expiry of an spc |
Free format text: PRODUCT NAME: DULOKSETIN Spc suppl protection certif: 2005002 Effective date: 20190903 |